对乳腺癌亚型新辅助化疗反应的预后影响
Anil Yıldiz1, Ahmet Bilici1, Ozgur Acikgoz1
1Department of Medical Oncology, Medical Faculty, Istanbul Medipol University, Istanbul, Turkey.
Journal of chemotherapy (Florence, Italy)
|February 14, 2024
概括
新辅助化疗 (NAC) 在HER2-阳性和三阴性乳腺癌中显示出更高的病理完整反应 (pCR) 率. 实现pCR是改善生存结果的关键预测因素.
科学领域:
- 在瘤学瘤学.
- 医疗成像医学成像
- 临床研究 临床研究
背景情况:
- 新辅助化疗 (NAC) 是乳腺癌的关键治疗方式.
- 了解不同乳腺癌亚型的治疗反应对于优化患者的治疗结果至关重要.
研究的目的:
- 评估接受NAC的乳腺癌患者的治疗反应,临床结果和生存率.
- 为了确定对NAC的病理完整反应 (pCR) 的预测标志物.
主要方法:
- 对139名接受NAC和后续手术的乳腺癌患者 (2014-2019) 的回顾性分析.
- 对不同乳腺癌亚型 (光线A,HER2阳性,三阴性,HER2阴性) 的pCR率进行比较.
- 多变量分析以确定无病生存期 (DFS) 和整体生存期 (OS) 的预后因素.
主要成果:
- 与光线A和HER2-阴性亚型相比,在HER2-阳性和三重阴性亚型中观察到显著更高的pCR率 (p=0.013).
- 瘤等级和pCR是DFS的独立预后因素.
- pCR是OS的独立预后指标.
- 18F-FDG PET/CT发现,HER2阳性和三阴性亚型独立预测了pCR.
结论:
- 在接受NAC治疗的乳腺癌患者中,pCR是改善存活率的重要预测因素.
- HER2阳性和三阴性亚型显示出对NAC的有希望的反应率.
- 识别预测标记,包括成像发现和亚型,对于定制NAC策略和改善患者存活率至关重要.
相关概念视频
01:21Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K